BGNE 📈 BeiGene - Overview

BeiGene, Ltd. is a global oncology company that focuses on discovering and developing innovative treatments for cancer patients. With a presence in the United States, China, Europe, and internationally, the company has established itself as a key player in the biotechnology industry. Its commercial-stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) that has shown efficacy in treating various blood cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia. Additionally, the company offers TEVIMBRA, an anti-PD-1 antibody immunotherapy that has been approved for the treatment of various solid tumor and blood cancers, including non-small cell lung cancer and renal cell carcinoma.

The company's pipeline also includes a range of clinical-stage products, such as BGB-11417, a small molecule Bcl-2 inhibitor that has the potential to treat various types of cancer, including leukemia and lymphoma. Other notable pipeline products include BGB-16673, a BTK-targeting chimeric degradation activation compound that has shown promise in treating patients with wild-type and mutant BTK, and Ociperlimab (BGB-A1217), a TIGIT inhibitor that is being evaluated as a potential treatment for various solid tumors. Furthermore, the company is developing Zanidatamab, a bispecific HER2-targeted antibody that has the potential to treat HER2-positive breast cancer and other solid tumors.

BeiGene, Ltd. has also established a number of strategic partnerships and collaborations with other biotechnology and pharmaceutical companies, including Ensem Therapeutics, Inc., Shandong Luye Pharmaceutical Co., Ltd., and Amgen Inc. These partnerships have enabled the company to expand its pipeline and accelerate the development of its products. With a strong focus on research and development, the company has a number of preclinical programs in place, including inhibitors of RAF, such as Lifirafenib and BGB-3245, and BGB-30813, which is being evaluated as a potential treatment for various types of cancer.

As a publicly traded company, BeiGene, Ltd. is listed on the NASDAQ stock exchange under the ticker symbol BGNE. The company was incorporated in 2010 and is headquartered in Camana Bay, the Cayman Islands. With a web presence at https://www.beigene.com, the company provides investors and stakeholders with access to information about its products, pipeline, and corporate activities. As a common stock, the company's shares are classified under the GICS Sub Industry: Biotechnology, and its ISIN is US07725L1026.